FDA Rejects Eisai’s Aquavan Injection
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory panel had voted in favor of propofol prodrug, with conditions; timeline for sedative’s resubmission is uncertain.
You may also be interested in...
Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage
Company was hoping to position Lusedra as an anesthetic that did not require the presence of an anesthesiologist.
Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage
Company was hoping to position Lusedra as an anesthetic that did not require the presence of an anesthesiologist.
Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition
Shionogi offers strong pipeline, Sciele brings 770-strong sales force to Japan-U.S. pairing.